

## Abstract

# Synthesis of Novel 2-Phenylindole Analogues as Antifungal and Antibacterial Agents <sup>†</sup>

Ke Yang and Xinhui Pan \* 

Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education,  
School of Pharmaceutical Sciences, Shihezi University, Shihezi 832002, China

\* Correspondence: panxhshzu@163.com

<sup>†</sup> Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022;

Available online: <https://ecmc2022.sciforum.net/>.

**Abstract:** A series of novel indole derivatives containing ester groups, halogen, epoxy and short-chain aliphatic hydrocarbons were designed, synthesized and evaluated for their antibacterial activities. Most of the compounds showed relatively excellent inhibitory activities against different strains (including a multidrug-resistant clinical isolate). Compounds **3f**, **3o** and **3r** showed the strongest inhibitory activity (mic of 2–32 µg/mL). Compounds **3f**, **3h**, **3i**, **3o** and **3r** with antibacterial activity were not cytotoxic against RAW 264.7 mouse macrophages. The structure–activity relationship analysis and docking studies showed that the halogens as well as aliphatic hydrocarbons could enhance the antibacterial ability and reduce the toxicity of the indole compounds.

**Keywords:** synthesis; anti-bacterial; anti-fungal; 2-phenylindole



**Citation:** Yang, K.; Pan, X. Synthesis of Novel 2-Phenylindole Analogues as Antifungal and Antibacterial Agents. *Med. Sci. Forum* **2022**, *14*, 128. <https://doi.org/10.3390/ECMC2022-13172>

Academic Editor: Maria Emília Sousa

Published: 1 November 2022

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



**Copyright:** © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

**Supplementary Materials:** The following are available online at <https://www.mdpi.com/article/10.3390/ECMC2022-13172/s1>.

**Author Contributions:** Conceptualization, X.P.; methodology, X.P.; experiment, K.Y.; software, K.Y.; validation, X.P.; formal analysis, K.Y.; investigation, K.Y.; resources, K.Y.; data curation, K.Y.; writing—original draft preparation, K.Y.; writing—review and editing, X.P.; supervision, X.P. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was supported by National Natural Science Foundation of China (82160651); The Open Project of Stake Key Laboratory of Natural and Biomimetic Drugs, Peking University (K202103); The Open Project of Key Laboratory of Xinjiang Phytomedicine Resource and Utilization, Ministry of Education (XPRU202004); Youth Innovative Talent Cultivation Projects of Shihezi University (CXPY202005) and The Open Sharing Fund for the Large-scale Instruments and Equipments of Shihezi University.

**Institutional Review Board Statement:** The animal study protocol was approved by the Ethics Committee of the First Affiliated Hospital, School of Medicine, Shihezi University (protocol code A2022-209-01).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** The data presented in this study are available in the article.

**Conflicts of Interest:** The authors declare no conflict of interest.